Biomedical Informatics Research Lab, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China; Cancer Genomics Research Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China; Big Data Research Institute, China Pharmaceutical University, Nanjing 211198, China.
Department of Electrical and Computer Engineering, University of California, San Diego, La Jolla, CA 92093, USA.
EBioMedicine. 2019 Apr;42:431-442. doi: 10.1016/j.ebiom.2019.03.068. Epub 2019 Mar 29.
Prior studies showed that tumor glycolysis and tumor immune evasion are interdependent. However, a systematic investigation of the association between tumor glycolysis and tumor immunity in various cancers remains lacking.
Using the Cancer Genome Atlas (TCGA) datasets, we explored the association between glycolytic activity and immune signatures in 14 cancer types. We also explored the associations between glycolytic activity and tumor immunity associated genetic features, including PD-L1 expression, tumor mutation burden (TMB), and tumor aneuploidy. Moreover, we performed in vitro experiments to verify some findings from bioinformatics analysis. Furthermore, we explored the association between tumor glycolytic activity and immunotherapy response.
Glycolytic activity was likely correlated with active immune signatures in various cancers and highly glycolytic tumors presented an immune-stimulatory tumor microenvironment. Compared to TMB and aneuploidy, glycolytic activity was a stronger and more consistent predictor for immune signatures in diverse cancers. Both computational and experimental analyses showed that glycolysis could increase PD-L1 expression in tumor. Glycolytic activity had a strong correlation with apoptosis which was a strong positive predictor for immune signatures, suggesting that apoptosis could be an important medium connecting glycolytic activity with immune activity in cancer. Finally, highly glycolytic tumors exhibited a better immunotherapy response and a favorable survival in the immunotherapy setting.
Tumor glycolysis may increase tumor immunity in diverse cancers. Glycolytic activity enhances PD-L1 expression on tumor cells and thus promotes anti-PD-1/PD-L1 immunotherapy response. Thus, the tumor glycolytic activity could be a predictive biomarker for immunotherapy response in diverse cancers. FUND: This work was supported by the China Pharmaceutical University (grant numbers 3150120001, 2632018YX01 to XW).
先前的研究表明,肿瘤糖酵解与肿瘤免疫逃逸是相互依存的。然而,系统研究各种癌症中肿瘤糖酵解与肿瘤免疫之间的关联仍然缺乏。
我们使用癌症基因组图谱(TCGA)数据集,探索了 14 种癌症类型中糖酵解活性与免疫特征之间的关联。我们还探索了糖酵解活性与肿瘤免疫相关遗传特征之间的关联,包括 PD-L1 表达、肿瘤突变负担(TMB)和肿瘤非整倍性。此外,我们进行了体外实验来验证生物信息学分析中的一些发现。此外,我们还探索了肿瘤糖酵解活性与免疫治疗反应之间的关联。
在各种癌症中,糖酵解活性与活跃的免疫特征可能相关,高度糖酵解的肿瘤呈现出免疫刺激性的肿瘤微环境。与 TMB 和非整倍性相比,糖酵解活性是各种癌症中免疫特征的更强和更一致的预测因子。计算和实验分析均表明,糖酵解可以增加肿瘤中 PD-L1 的表达。糖酵解活性与细胞凋亡密切相关,细胞凋亡是免疫特征的强烈正预测因子,这表明细胞凋亡可能是癌症中糖酵解活性与免疫活性之间的重要中介。最后,高度糖酵解的肿瘤在免疫治疗环境中表现出更好的免疫治疗反应和良好的生存。
肿瘤糖酵解可能会增加多种癌症中的肿瘤免疫。糖酵解活性增强肿瘤细胞上的 PD-L1 表达,从而促进抗 PD-1/PD-L1 免疫治疗反应。因此,肿瘤糖酵解活性可以作为多种癌症免疫治疗反应的预测生物标志物。
本工作得到中国药科大学(项目编号 3150120001、2632018YX01 给 XW)的支持。